Phaseline

Companies › PDC*line Pharma SAS

PDC*line Pharma SAS: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PDC*lung01
Dendritic cell vaccine loaded with synthetic peptides from lung tumor antigens (NY-ESO-1,
PRAME, MAGEA3, MAGEA4Phase 1Non Small Cell Lung Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03970746PDC*lung01Phase 1Non Small Cell Lung CancerOncologyJul 2024

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

PRAME (1) MAGEA3 (1) MAGEA4 (1)

Companies with the same targets

Immunocore Neowise Biotechnology Immatics US OSE Immunotherapeutics Zelluna Immunotherapy CDR-Life USWM CT

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.